top of page
Search

J&J Reports Strong 12-Month Results for Varipulse PFA Platform in AFib Treatment

  • Writer: nuaxia
    nuaxia
  • 4 hours ago
  • 1 min read

VARIPURE study data highlights high arrhythmia-free rates and low adverse events, alongside expanded CE mark enabling broader ablation strategies.


Johnson & Johnson has reported 12-month interim results from the VARIPURE study, showing 84.2% freedom from atrial arrhythmia recurrence and a low 0.8% adverse event rate in patients treated with its Varipulse pulsed field ablation platform.


The updated CE mark allowing ablation beyond pulmonary veins further strengthens the platform’s potential in treating more complex atrial fibrillation cases.


Alert Type

Clinical Data / Study Update

Drug/Device Name

Varipulse PFA Platform (Varipulse catheter, Trupulse generator, Carto 3 mapping system)

Indication

Atrial fibrillation (AFib), including paroxysmal and persistent AFib

Therapy Area(s)

Cardiology, Electrophysiology

Geography

Europe

What Changed

Johnson & Johnson reported 12-month interim results from the VARIPURE study, showing 84.2% freedom from atrial arrhythmia recurrence and a low 0.8% adverse event rate in AFib patients treated with the Varipulse PFA platform. The device also received an updated CE mark enabling ablation beyond pulmonary veins.

Clinical Relevance

Demonstrates strong real-world efficacy and safety for pulsed field ablation, with expanded treatment capability for persistent AFib and broader ablation strategies, potentially improving outcomes in complex arrhythmia patients.

Source Link

https://www.jnj.com/

Date

16-Apr-2026

Status

Draft

Notes

VARIPURE study includes 1,023 patients across 22 European sites; 12-month data available for 442 patients. Results presented at EHRA 2026 and published in Europace. Varipulse Pro recently launched in Europe.

 



Discover how nuaxia can support your next medical education initiative:

 
 
 

Comments

Rated 0 out of 5 stars.
No ratings yet
Add a rating
bottom of page